Gene encoding transglutaminase derived from fish

Abstract: This invention provides a DNA fragment having a gene derived from fish which codes for a polypeptide possessing transglutaminase activity, a recombinant plasmid comprising said DNA, a transformant into which said plasmid is introduced, and a method for the production of a fish-derived polypeptide possessing transglutaminase activity, by culturing said transformant.

Description: Field of the Invention The present invention relates to a DNA fragment having a gene naturally occuring in Pagrus major which codes for a polypeptide possessing transglutaminase activity, wherein the polypeptide includes the sequence of 694 amino acid residues of SEQ ID NO:2, a recombinant plasmid comprising said DNA, a transformant into which said plasmid is introduced, and a method for the production of a Pagrus major-derived polypeptide possessing transglutaminase activity, characterized by culturing said transformant. Description of the Prior Art Transglutaminase (hereafter abbreviated as "TGase") is an enzyme which catalyzes an acyl group transfer reaction of a gamma-carboxyamido group of a glutamine residue in a peptide chain. In the presence of transglutaminase, when an epsilon-amino group of a lysine residue in a protein functions as an acyl receptor, epsilon-(gamma-Gln)-Lys crosslinkings are formed in the protein or between two or more protein molecules, or if a primary amine such as an amino acid, amino acid derivative, etc. functions as an acyl receptor, it is introduced into the protein. Also, when water functions as an acyl receptor, transglutaminase enzyme promotes the reaction where the glutamine residue undergoes deamidation to a glutamic acid residue. TGase is used in the production of gelatinous food products and cosmetics, as well as yogurt, jelly and cheese, etc. (Japanese Patent Publication 50382/1989). Further, it is used for the production of materials for thermostable microcapsules, carriers for immobilized enzymes, etc. A microorganism-derived TGase which has been discovered is a calcium (Ca 2+ )-independent TGase from bacteria of genus Streptoverticillium . Some concrete examples of bacteria belonging to said genus include Streptoverticillium griseocarneum IFO 12776, Streptoverticillium cinnamoneum sub sp. cinnamoneum IFO 12852, streptoverticillium mobaraense IFO 13819, etc. (Japanese Patent Application Publication 27471/1989). Further, TGase derived from mammalian animals is also known. For example, one derived from guinea pig liver (Connellan, et al., Journal of Biological Chemistry, Vol. 246, p.1093-1098, 1971), one derived from human or bovine vascular endothelial cells (Gentile, et al., Journal of Biological Chemistry, Vol. 266, p.478-483, 1991, and Nakanishi, et al., European Journal of Biochemistry, Vol. 202, p.15-21, 1991), and human blood coagulation factor XIII (Takahashi, et al., Proc. Natl. Acad. Sci. USA, Vol. 83, p.8019-8023, 1986), are known. Problems to be solved by the Present Invention Heretofore, the sources of TGase available for industrial use have been mammals and bacteria. However, the TGase processed products with which we are most familiar on a daily basis are processed marine products, a typical example of which is boiled fish paste "kamaboko" (Seki, et al., Nippon Suisan Gakkaishi, Vol. 56, p.125-132, 1990), and the TGase functioning in this case is obviously an enzyme derived from fish. In the past, absolutely no information has been reported on a TGase gene from fish. Also, if it becomes possible to produce fish TGase at a low price, not only will the range of industrial use of TGase widen, but it will be possible to provide a natural-like enzyme-processed marine product. Thus, it is desirable that fish TGase gene gene is cloned, analyzed and expressed by biotechnological method for the purpose of establishing a system for supplying fish-derived TGase at a low price. Biochemistry, 1988, 27, 2898-2905 discloses the cloning of a cDNA encoding guinea pig liver transglutaminase. Chemical Abstracts, Vol. 113, No. 21, 1990, Colombo, Ohio, US, abstract no. 189898q discloses the presence of transglutaminase activity in Alaska pollack muscle. J. Biol. Chem., Vol. 264, No. 1, pages 312-316 (1989) is a document disclosing examples of homology on the protein level between mammals and fish. The homologies between human proteins and proteins derived from fish are very low. A comparison of the cDNA sequence of guinea pig (cavia porcellus ) transglutaminse and the cDNA sequence of Alaska pollack (theragra chalcogramma) transglutaminse is obtainable from Genbank acc. numbers M19646 and E08616, respectively. J. Biol. Chem., Vol. 266, No. 1, 1991, pages 478-483 "Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases" discloses the sequence of a human transglutaminase. Summary of the Invention The inventors of the present invention carried out diligent research in order to overcome the above mentioned problems, and succeeded in acquiring a DNA fragment which contains a gene naturally occuring in Pagrus major which codes for TGase, and determining the base sequence thereof. Based on these results, the expression of said gene has become possible by genetic engineering methods using as a host a microorganism such as E. coli , Bacillus subtilis; yeast, fungus, etc., and thus a way has been found for the efficient mass production of a polypeptide possessing transglutaminase activity. In other words, the present invention relates to a DNA fragment having a gene naturally occuring in Pagrus major which codes for a polypeptide which possesses TGase activity, a recombinant plasmid comprising said DNA, a transformant into which said plasmid is introduced, and a method for the production of said polypeptide characterized by culturing said transformant, as well as the polypeptide obtained by said production method. Particular DNA sequences and amino acid sequences coded for by such gene sequences encompassed by the present invention are the following: ID No. 2, 3 and 4 of the sequence protocol as defined in the enclosed claims. The present invention also includes a DNA fragment as defined in these claims having a gene naturally occuring in Pagrus major which codes for a polypeptide possessing transglutaminase activity, having a naturally occurring or artificial substitution, deletion, insertion or inversion of one or more bases in the base sequence. As a method for obtaining the DNA fragment containing a gene naturally occuring in Pagrus major which codes for a polypeptide possessing transglutaminase activity according to the present invention, we the inventors of the present invention have employed a method whereby a synthesized DNA fragment coding for the amino acid residues near the active center of guinea pig tranglutaminase (Sequence ID No. 10) is used as a probe for colony hybridization isolation of the desired DNA fragment from the cDNA prepared from tissue of fish. In the past, the fact that a high degree of homology exists between guinea pig transglutaminase or its gene, and Pagrus major transglutaminase or its gene has been completely unknown, and thus the success of cloning of the desired DNA fragment using this method has been unexpected. In addition to the above, other methods of acquiring a Pagrus major-derived DNA fragment containing the gene which codes for a polypeptide possessing transglutaminase activity according to the present invention include those mentioned below. A) Isolation and purification of the Pagrus major-derived polypeptide which possesses transglutaminase activity, and chemical synthesis of the entire base sequence based on the determined entire amino acid sequence. B) Synthesis of a portion of the base sequence based on the determined amino acid sequence, and use of this as a probe for cloning from the cDNA bank or genomic bank. Here, the cloning method may be the hybridization method or the PCR method; and C) Supplying mRNA transcribed from cDNA to an in vitro translation system of wheat germ or rabbit reticulocytes, determination of the section in which mRNA for a polypeptide which possesses transglutaminase activity is present, and cloning therefrom of the desired cDNA fragment. Examples of DNA fragments having the gene which codes for a Pagrus major-derived polypeptide possessing transglutaminase activity according to the present invention include those coding for polypeptides listed as Sequence ID No. 2 and 3 of the sequence list. The DNA fragment may include a variety of different base sequences, from the point of view of degeneracy of the genetic codon. These base sequences may be easily selected by any skilled in the art, depending on the various elements of the gene expression system, for example, use of the preferable codon corresponding to the type of the host cell, and avoiding of a secondary structure formed in the transcribed RNA, etc. Concrete examples include the naturally occurring base sequences listed as Sequence ID No. 4 in the sequence list. Further, the DNA base sequence may be a result of cloning from natural occurring entity, or an artificially chemically synthesized DNA. The present DNA fragment has a multiplicity derived from mult-copies of gene-dosage, for example, which may be a pseudogene. However, such still contain an essentially equivalent DNA fragment capable of expressing the transglutaminase activity. The presence of them is describe in the following examples. The present invention may also provide the desired enzyme through expression of Pagrus major-derived transglutaminase gene in a microorganism transformed by genetic recombinant technology. The recombinant plasmid used in this case may be prepared by insertion of the DNA fragment having the Pagrus major-derived gene which codes for a polypeptide possessing transglutaminase activity into a publicly known expression vector corresponding to the desired expression system, using a publicly known method of the prior art. Expression vectors for E .coli include an expression vector plasmid with a high expression of a fused protein composed of T7gene10, a linker peptide and a desired protein (Xpress System™, manufactured by Invitrogen Co.), and an expression vector plasmid with a high expression of a fused protein composed of glutathione-S-transferase and a desired protein (pGEX-2T or pGEX-3T vector plasmid manufactured by Pharmacia LKB Co.). More preferable expression vectors are pBSF2-SD7 and pT13sNco. On the other hand, an example of an expression vector for yeast Saccharomyces is pYES2 "(Invitrogen Co.) which may use a promoter for GAL1 , the gene which codes for galactokinase, for the expression of a foreign gene. The present invention also relates to various transformants obtained by introduction of the recombinant plasmid which carries the transglutaminase gene. Some organisms which can be used for the host of transformation include procaryotic cells such as E. coli , Bacillus subtilis , etc. as well as eucaryotic cells such as yeast, fungi, etc., and the organism is preferably E.coli or yeast, more preferably E.coli HB101 or Saccharomyces cerevisiae INVSC2 strains. These transformants are capable of producing and accumulating said enzyme in the cells or in the culture medium. Finally, the present invention relates to a method for the production of a polypeptide possessing transglutaminase activity, by the culturing of the above mentioned transformant. The culturing conditions may be determined as deemed appropriate by one skilled in the art depending on the type of host used. Also, said enzyme which is expressed and accumulated in the cells or secreted into the culture medium may be isolated and purified using a number of publicly known methods of the prior art. Concretely, in a purification process similar to that applied to natural transglutaminase from the tissues, this recombinant transglutaminase(s) can be purified from the crude extracts. It has not been reported that transglutaminase derived from fish possess saccharide chains. The Pagrus major-derived transglutaminase produced in E. coli may not be added with any saccharide chains, but the transglutaminase produced in yeast may be added with some saccharide chains in accordance with the function of the glycosylation mechanism in yeast cell. As a recombinant transglutaminase for reforming food proteins, mentioned is one derived from a guinea pig. This is referred to as one which is available at present for comparative investigation, and a transglutaminase derived from Pagrus major is superior to this for industrial use with respect to the following points. 1) A fish like Pagrus major is an animal which has heretofore been eaten by human being for a long period of time even as a raw meat thereof, and the safety of the transglutaminase as being in this is said to be extremely high. In future, in consideration of the use of a transglutaminase in food proteins, the cost to be spent for investigation of the safety of the fish-derived transglutaminase may be considered to be smaller than that of one derived from any other living things. 2)Regarding the difference in the enzymatic characteristics between the fish-derived transglutaminase and one derived from other mammals especially for application thereof to fish paste products, specifically mentioned are the difference in the reactivity of the enzyme and the production cost to be influenced by the difference in the deactivating conditions of the enzyme to be reacted (this will be referred to in the following examples) and also the difference in the qualitative effects such as the natural taste and tooth feeling (expression of elasticity) of the reaction products. In fact, it has been found that a fish transglutaminase like Pagrus major transglutaminase has a high reactivity to a fish actomyosin (refer to the following examples). 3)The difference in the productivity of a recombinant transglutaminase with microorganisms is also an important problem for consideration of the practical use of the transglutaminase. Ikura et al. have already reported the production of a guinea pig-derived transglutaminase with Escherichia coli (Eur. J. Biochem., Vol. 187, 705-711, 1990). However, the amount of it to be produced is extremely small. That is, the transglutaminase in an extract of transglutaminase-producing cells was such that could only be detected with an antibody thereto (the amount of the transglutaminase to be produced is about 2.6 mg or so per liter of the culture medium). As opposed to this, where the DNA fragment coding for the Pagrus major-derived transglutaminase of the present invention is applied to a host of E. coli , it shows a productivity of producing about 10% to 15% of E. coli -derived SDS-soluble total proteins, reaching the expression quantity about 100 times or higher than that of the guinea pig-derived transglutaminase. Thus, there is a high possibility that the Pagrus major-derived transglutaminase would have a gene structure suitable to production of a recombinant one. (This will be explained in the following examples.) The above-mentioned various characteristics of the Pagrus major-derived transglutaminase would yield great advantages in consideration of application of a transglutaminase to industrial use, especially for reformation of food proteins therewith. The shortage of marine resources due to the 200 nautical sea mile restriction and the total fish catch quota restriction in the fishery sea area in these days causes the elevation of the raw material cost in producing marine products, which is being a serious problem. For instance, in the case, use of the enzyme of the present invention with other edible protein could reduce the concentration of the fish paste material in the processed marine products. Also it could lead to the effective use of the underutilized marine resources. On the other hand, the Pagrus major-derived transglutaminase is quite different from a microorganisms (bacteria)-derived transglutaminase (hereinafter referred to as BTG) with respect to the structure and the reaction mechanism. For instance, BTG does not need calcium ion for expressing the enzymatic function thereof. Due to this, differentiation in use of the BTG from the Pagrus major-derived transglutaminase to be obtained by the present invention would be necessary for the intended protein to be utilized. As to the difference between BTG and the Pagrus major-derived transglutaminase, the following may be referred to. For instance, where the Pagrus major-derived transglutaminase is reacted with a substrate or where the reaction is desired to be stopped, the calcium ion dependence could be utilized so as to control the reaction time and the reactivity of the enzyme. Also the Pagrus major-derived transglutaminase is less stable against heat than BTG, so the Pagrus major-derived transglutaminase can be denatured at relatively low temperature, which can be a merit for production of anti-heat food. A more detailed explanation of the present invention is given below, with reference to the examples. Examples 1. DNA fragment having a gene which codes for transglutaminase from Pagrus major. Using polytron and a teflon homogenizer, 1.3 g of the liver from Pagrus major was crushed in a solution (20 ml) of 4 M guanidine thiocyanate and 1% beta-mercaptoethanol. After 0.5% sodium lauryl sarcosinate was added to and dissolved in the resulting cell suspension, the obtained solution was passed through a 23 gauge hypodermic needle 10 times to shear the chromosomal DNA. Next, the solution was centrifuged at 4°C, 5000 rpm for 20 minutes and the supernatant recovered. The total RNA was further purified by a conventional method, through CsCl density gradient centrifugation of the supernatant (Sambrook et al., Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, 1989). The total amount of RNA obtained was 3.8 mg. Of this total RNA, 1.3 mg was supplied to an mRNA purifying kit (Clontech) using an oligo (dT)-cellulose column, and approximately 20 µg of purified mRNA molecules were obtained. Of the obtained mRNA, 8 µg were used as a template for cDNA preparation. A random primer was used for cDNA synthesis, and a You-prime cDNA synthesis kit (Pharmacia) was used to synthesize double-stranded cDNA. The obtained cDNA was then incorporated into a λ-phage vectro-λZapII (Stratagene) at its restriction enzyme site Eco RI, after which a GIGAPACKIIGOLD (Stratagene) packaging kit was used to prepare and acquire a cDNA library of Pagrus major incorporated in the phage. The titer of this library was 1.2 x 10 6 pfu/µg vector. A host cell E. coli XL1-Blue was infected with 6.0 X 10 4 pfu of phage from said cDNA library of Pagrus major , after which it was spread onto 4 agar plates of diameter 150 mm at 1.5 X 10 4 pfu per plate. The cells were cultured at 37°C for about 9.5 hours, and then the phage plaques formed on the plates were transfered onto a nylon membrane (Hibond-N, manufactured by Amersham). Next, the nylon membrane was treated with an alkali to denature the DNA, neutralized and washed. Then, the membrane was treated at 80°C for 3 hours to immobilize the DNA onto the membrane. Prehybridization of the prepared nylon membrane was then effected at 42°C for 2 hours, followed by hybridization at 42°C for 16 hours. The composition of the prehybridization solution was 6XSSC (composition of 1XSSC: 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 5X Denhardt's solution (composition of 1X Denhardt's solution: 0.02% BSA, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone), 20% formamide, 100 µg/ml of herring testis DNA and 0.1% SDS. Also, the DNA probe used for the hybridization was a synthesized DNA fragment (5'-GTCAAGTACGGCCAGTGCTGGGTCTTCGC-3'; Ikura et al., Biochemistry, 27 , 2898-2905, 1988: Sequence ID No. 10) encoding amino acid residues located near the active center of guinea pig transglutaminase, labeled at the 5' terminal end with [gamma- 32 P] ATP. The candidate strains for the positive clones obtained by this screening were further subjected to the second and the third screening to finally obtain 4 positive clones. Each positive clone carrying the above-mentioned respective 4 positive cDNAs was then infected with helper phage (R408) to transform the cDNA derived from each of the positive clones into phagemid vector pBluescriptSK(-). The length of the inserted cDNA of each of the 4 clones was 0.5 kbp (kilobase pairs), 1.5 kbp, 2.5 kbp or 1.0 kbp, and they were named pSLTG2, pSLTG4, pSLTG5 and pSLTG6, respectively. Next, a restriction enzyme map for each of the cDNA clones was made, and Southern blotting analysis was done with the inserted cDNA of pSLTG5 as the probe. As it was made clear that pSLTG5 (with inserted cDNA length 2.5 kbp) included the other 3 cDNA clones, the DNA base sequence for the inserted cDNA of pSLTG5 was determined. Analysis of the base sequence was done with a Sequenase Version 2.0 (U.S.B. Co.) kit, according to a publicly known method of the prior art. The results showed a DNA sequence containing 2520 base pairs listed as Sequence ID No. 5 in the sequence list. Also, the restriction enzyme map of pSLTG5 is shown in Fig. 1. The DNA sequence contained the segment which showed a very high degree of homology with the DNA probe used by the inventors of the present invention. Also, the amino acid sequence deduced from this base sequence is listed as Sequence ID No. 2 in the sequence list. This amino acid sequence includes an active center sequence of 8 amino acid residues, Tyr-Gly-Gln-Cys-Trp-Val-Phe-Ala (Nakanishi et al., Eur. J. Biochem., 202, 15-21, 1991) which is present both in transglutaminase derived from guinea pig liver and in human blood clotting factor XIII. The E. coli strain (AJ12673) carrying the DNA plasmid pSLTG5 which contains the Pagrus major transglutaminase cDNA obtained as described above, Escherichia coli XL1-Blue/pSLTG5 is deposited as FERM BP-4114. All strains deposited under the designation "FERM" are deposited at the Fermentation Research Institute, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan. 2. A DNA fragment having a gene which codes for transglutaiminase from Alaska pollack, Theragra chalcogramma , (comparative example) Using a polytron and a teflon homogenizer, 2.3 g of Alaskan pollack liver were crushed in a solution (20 ml) of 4 M guanidine thiocyanate and 1% beta-mercaptoethanol. After 0.5% sodium lauryl sarcosinate was added to and dissolved in the cell suspension, the resulting solution was passed through a 23 gauge hypodermic needle 10 times to shear the chromosomal DNA. Next, the solution was centrifuged at 4°C, 10000 rpm for 20 minutes and the supernatant recovered. The total RNA was further purified by a conventional method, through CsCl density-gradient centrifugation of the supernatant (Sambrook et al., Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, 1989). The total amount of RNA obtained was 7.2 mg. Of this total RNA, 2.3 mg was subjected to an mRNA purifying kit (Clontech) using an oligo (dT)-cellulose column, and approximately 23 µg of purified mRNA used for molecules were obtained. Of the obtained mRNA, 4 µg were used as a template for cDNA synthesis. A random primer was DNA synthesis, and a You-prime cDNA synthesis kit (Pharmacia) was used to synthesize double-stranded cDNA. The obtained cDNA was then incorporated into lambda-phage vector-lambda ZapII (Stratagene) at its restriction enzyme cutting site EcoR I, after which a GIGAPACKIIGOLD (Stratagene) packaging kit was used to produce and acquire an Alaska pollack cDNA library incorporated in the phage. The titer of the library was 4.1 x 10 5 pfu/µg vector. A host cell E. coli XL1-Blue was infected with 5.8 X 10 4 pfu of phage from said Alaska pollack cDNA library, after which it was spread onto 4 agar plates of diameter 150 mm at 1.5 X 10 4 pfu per plate. The cells were cultured at 37°C for about 9.5 hours, and then the phage plaques formed on the plates were transfered onto a nylon membrane (Hibond-N, manufactured by Amersham). Next, the nylon membrane was treated with an alkali to denature the DNA, neutralized and washed. Then, the membrane was treated at 80°C for 3 hours to immobilize the DNA onto the membrane. Prehybridization of the prepared nylon membrane was then effected at 42°C for 2 hours, followed by hybridization at 42°C for 16 hours. The composition of the prehybridization solution was 6XSSC (composition of 1XSSC: 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 5X Denhardt's solution (composition of 1X Denhardt's solution: 0.02% BSA, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone), 20% formamide, 100 µg/ml of herring testis DNA and 0.1% SDS. Also, the DNA probe used for the hybridization was a DNA fragment of approximately 300 base pairs (DNA which may code for the region including the amino acid sequence near the active center) which could be cut off from Pagrus major liver transglutaminase cDNA listed as Sequence ID No. 4 in the sequence list using restriction enzymes Cla I and Bam HI, followed by random labeling with [α- 32 P] dCTP. The candidate strains for the positive clones obtained by this screening were further subjected to the second and the third screenings to finally obtain 8 positive clones. Each positive clone carrying the above-mentioned respective 8 positive cDNAs was then infected with helper phage (R408) to transfer the cDNA derived from each of the positive clones into phagemid vector pBluescript SK(-). The eight clones were named pALTG1, pALTG2, pALTG3, pALTG6, pALTG7, pALTG8, pALTG9 and pALTG10, respectively. Of these, the lengths of the inserted cDNA of pALTG1, 3, 6 and 8 were verified, a restriction enzyme map was made, and the cDNA base sequences were analyzed at the 5' end and the 3' end to find the correlation between each clone, shown in Fig. 2. Here, a Fluorescent Primer Cycle Sequencing Kit (manufactured by A.B.I. Co.) was used for analysis of the base sequences. Next, synthetic primers (20 bases) for the sequencing were prepared based on a portion of the base sequence of the obtained cDNA to determine the entire base sequence of the inserted cDNA of pALTG8. Analysis of the base sequence was done by a publicly known method of the prior art, using a Sequenase Version 2.0 (U.S.B. Co.) kit. The results showed a DNA sequence of 2921 base pairs listed as Sequence ID No. 9 in the sequence list. Also, the amino acid sequence deduced from this base sequence is listed as Sequence ID No. 6 in the sequence list. This amino acid sequence includes an active center sequence of 8 amino acid residues, Tyr-Gly-Gln-Cys-Trp-Val-Phe-Ala (Sequence ID No. 11) which is present both in transglutaminase derived from guinea pig liver and in human blood clotting factor XIII. The E. coli strain (AJ12709) holding the DNA plasmid pALTG8 which contained the Alaska pollack transglutaminase cDNA obtained as described above, Escherichia coli XLI-Blue/pALTG8, is deposited as FERM BP-4115. On the other hand, Alaska pollack-derived transglutaminase of expressing in other tissues than liver has also been investigated. For instance, cloning of a transglutaminase cDNA from Alaska Pollack muscular tissue has been attempted. 11.5 g of Alaska Pollack muscular tissue were ground in 80 ml of an 1% beta-mercaptoethanol solution of 4 M guanidine thiocyanate, using polytron and a teflon homogenizer. 0.5% sodium lauryl sarcocinate was added to and dissolved in the resulting cell suspension, and the solution was passed through a 23-gauge hypodermic needle seven times and successively through a 25-gauge injection needle seven times, whereby the chromosomal DNA was fragmented. Next, the solution was subjected to centrifugation of 10,000 rpm for 20 minutes at 4°C or lower, and the supernatant was collected. From the supernatant, a complete RNA was purified by CsCl density gradient centrifugation of a conventional manner (refer to Sambrook et al, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press (1989)). The amount of the thus obtained complete RNA was 2.1 mg. 1.7 mg of it was applied to an mRNA purifying kit (Clontech) using an oligo(dT)-cellulose column, to purify the mRNA molecule, the yield of which was about 21 microgram. Of the thus obtained mRNA, 3.2 microgram was used as a template for synthesis of cDNA. For synthesis of cDNA, a random primer was used, and a Time Saver cDNA synthesis kit (Pharmacia) for preparing a double-stranded cDNA was used. Plaque hybridization using the above cDNA library, was effected in the same manner where the DNA frgment coding for transglutaminase derived from Allaska pollack liver was obtained. But no positive cDNA clone could be obtained. Therefore, a cDNA fragment was obtained by the method which will be mentioned below in detail. The oligonucleotides as synthesized on the basis of the gene base sequence of Alaska pollack liver-derived transglutaminase, using the prepared Alaska pollack muscular cDNA group as a template, was used as primers, and a cDNA fragment of Alaska pollack muscular transglutaminase was specifically amplified by a PCR method (polymerase chain reaction method) using Amplitaq DNA Polymerase (Takara Shuzo). As shown in Fig. 10, used were Pr. 10 (sequence, 5'-TTGGAAGCTTGTAAGAGCAACTCTTGGAAA-3') and Pr. 970 (sequence, 5'-TTGTACACTCGATCGATGGAGAGGT-3') both as primers for synthesizing the cDNA fragment, for the 5' terminal region (the region coding for N-terminal region of transglutaminase) in the expected Alaska pollack muscle-derived transglutaminase cDNA structure. After PCR, a DNA fragment of about 980 bp was amplified. Next, the terminal of the fragment was made blunt and then inserted into the restriction enzyme Hin cII cleaved site of pUC18 vector. For the gene amplification of the center region, used were Pr. 620 (sequence, 5'-TCTGCTTTGGGATCCTTGACCGCT-3') and Pr. 2000 (sequence, 5'-TGAAGGAGAGCTCCACAGACACA-3') both as synthetic oligonucleotide primers. Into these primers, were artificially inserted a restriction enzyme Bam HI cleavage recognizing site and a restriction enzyme Sac I cleavage recognizing site, respectively. After PCR reaction, the amplified DNA fragment of about 1.4 kbp was prepared, and this was digested with the preceding enzymes to give DNA fragments, which were inserted into the same restriction enzyme sites of pBluescript IISK- to obtain cDNA clones. Further, for amplification of the cDNA fragment in the 3' terminal region (the region coding for C-terminal region of transglutaminase), the intended region was first amplified with PCR primers Pr. 10-1F (sequence, 5'-ATGATGTCAAAGGCTGTCAC-3') and Pr. 8-1R (sequence, 5'-TCTTACCATATAAGTTGTAA-3'). However, since the primers caused amplification of other small fragments than the intended DNA fragment, the thus amplified DNA group was again subjected to gene amplification, using the same primer Pr. 10-1F and a novel primer of Pr. 3-2F2R (sequence, 5'-ATTGATTAACAACAAAATGG-3') as templates. As a result, a DNA fragment of about 800 bp was amplified. The both terminals of the present cDNA fragment were also made blunt in the same manner as mentioned above, and the resulting cDNA fragments were inserted into the restriction enzyme Eco RV site of pBluescript IISK-. A plasmid having the cDNA fragment having each of the above-mentioned three regions was applied to E. coli XLl-Blue for transformation, whereby N-terminal clones of Nos. N-3, N-4 and N-5, center region clones of Nos. SB-4, SB-5, SB-21, SB-22, and SB-30 and C-terminal clones of Nos. C-6, C-9 and C-13 were obtained. Next, the base sequence of each of the above-mentioned eleven DNA clones was sequenced by a known method using Applied Biosystems' Tag dideoxy Terminator Cycle Sequencing Kit. As a result, two kinds of genes coding for transglutaminase were present in Alaska pollack muscule, the one having DNA sequence as shown as SEQ ID NO:51 in the Sequence List and the other having DNA sequence as same structure as the Alaska pollack liver-derived transglutaminase cDNA as shown as SEQ ID NO:8. From the above, it was clarified that the transglutaminase of SEQ ID NO:8 is an Alaska pollack transglutaminase as expressed beyond the kind of the organ; and that the transglutaminase of SEQ ID NO:51, though could not be obtained as a cDNA of a complete length, was different from the liver-derived transglutaminase only in the point of a several base substitution and the base deletion of 12 bp and the base insertion of 3 bp in the structural gene. Thus, the both genes were clarified to be highly homologous to each other. An E. coli strain (AJ 12790) of E. coli XLI-Blue/N3 having plasmid N3 containing a part of the Alaska pollack muscle-derived transglutaminase cDNA fragment (SEQ ID NO:51) obtained in the manner as above has been deposited in Fermentation Research Institute of Japan as FRI Deposition No. 4147 (FERM BP-4147); an E. coli strain (AJ 12791) of E. coli XLI-Blue/N5 having plasmid N5 as FRI Deposition No. 4148 (FERM BP-4148); an E. coli strain (AJ 12792) of E. coli XLI-Blue/SB4 having plasmid SB4 as FRI Deposition No. 4149 (FERM BP-4149); an E. coli strain (AJ 12793) of E. coli XLI-Blue/SB5 having plasmid SB5 as FRI Deposition No. 4150 (FERM BP-BP-4150); an E. coli strain (AJ 12794) of E. coli XLI-Blue/SB21 having plasmid SB21 as FRI Deposition No. 4151 (FERM BP-4151); and an E. coli strain (AJ 12795) of E. coli XLI-Blue/SB22 having plasmid SB22 as FRI Deposition No. 4152 (FERM BP-4152). 3. Construction of plasmid pIL6TG1 which express the Pagrus major transglutaminase gene, and its introduction into E. coli and verification of physiological activity of TGase produced by the transformant Plasmid pSLTG5 having the Pagrus major transglutaminase gene (cDNA) prepared in the above example was digested with restriction enzymes Xba I and Eco RV, as shown in Fig. 3, and a DNA fragment containing the transglutaminase cDNA was obtained. On the other hand, expression vector pBSF2-SD7 possessing tryptophan promoter and trpA terminator was digested with Bam HI, and then the DNA cut ends were made blunt with Klenow enzyme, and then treated with Xba I to obtain a large DNA fragment possessing tryptophan promoter. Expression plasmid pBSF2-SD7 is the plasmid listed in Bio/Technology , 8 , p.1036-1040, 1990. The two DNA fragments obtained by the above described treatment were ligated together with T4DNA ligase to obtain the Pagrus major transglutaminase cDNA expression plasmid pIL6TG1. Verification of the DNA base sequence of this pIL6TG1 showed that one GC base pair was missing at the Bam HI cleavage site, making it clear that the Eco RV site was present upstream from the trpA terminator in the plasmid. A publicly known method was used to introduce pIL6TG1 into E. coli HB101, and a transformant, Escherichia coli HB101/pIL6TG1, (AJ12730) was prepared. AJ12730 is deposited as FERM BP-4116. A colony of the acquired transformant was applied onto an agar plate containing 200 µg/ml of ampicillin, and cultured at 30°C overnight, after which approximately 2 cm 2 of the lawn of growing cells from the plate were inoculated into a Sakaguchi flask containing 100 ml of an M9 casamino acid culture medium supplemented with 2% glucose, 200 µg/ml of leucine, 200 µg/ml of proline, 2.0 µg/ml of thiamine-HCl, and 200 µg/ml of ampicillin. The mixture was cultured at 30°C for about 16 hours to collect the cells. To the collected cells were added 0.3 ml of a 0.5 M EDTA solution, and 30 ml of a mixture of 20 mM Tris-HCl and 30 mM NaCl, to prepare a suspension. Further, 1 ml of a 4 mg/ml lysozyme solution was added thereto and the mixture was stirred and then allowed to stand at 0°C for 1 hours. After this, the cell suspension was subjected to ultrasonic crushing and centrifuged (8000 rpm for 10 minutes) to prepare a supernatant from the crushed cells. Also, a supernatant from centrifugation of the crushed cells was prepared in the same manner from E. coli ( E. coli HB101/pBSF2-SD7) possessing a plasmid with no transglutaminase cDNA. The transglutaminase activity of each of the supernatants was verified according to an activity detection method which measures the change in fluorescence intensity (fluorescence intensity at 480 nm with 350 nm wavelength exciting light) due to bonding of monodansyl cadaverine with dimethylated casein. This activity detection method is based on the method described in Nippon Suisan Gakkaishi (1991), Vol. 57, pp.1203-1210, with a few modifications. That is, 150 µl of each of the test samples was added to a solution (adjusted to 2.5 ml after addition of the samples) composed of 1 mg/ml of dimethylated casein, 15 µM of monodansyl cadaverine, 5 mM of CaCl 2 , 50 mM of Tris-HCl (pH 7.5) and 3 mM of DTT, which was stirred and kept at 37°C for 30 minutes. After the reaction, EDTA solution was added to a final concentration of 10 mM, and the fluorescence intensity of each of the reaction solutions was measured using a fluorescence intensity meter (Shimazu RF-520). Strain TG cDNA Relative fluorescence intensity pBSF2-SD7/HB101 absent 9 pIL6TG1/HB101 present 257 Note: TGcDNA = transglutaminase cDNA The results, which can be seen in Table 1, clearly show that transglutaminase activity was present in the cell extract of E. coli which possesses an expression plasmid having transglutaminase cDNA obtained in the example described above. It became obvious from this that the cDNA obtained was capable of coding for transglutaminase. 4. Construction of plasmid pTTG2-22 which expresses the Pagrus major transglutaminase gene, and its introduction into E. coli and verification of physiological activity of TGase produced by the transformant Next, in order to further produce a large amount of transglutaminase, we made an improvement in the transglutaminase expression plasmid. An explanation thereof is given below. Since the amount of transglutaminase expressed by transglutaminase expression plasmid pIL6TG1 obtained in Example 3 was small, further diligent research was conducted in order to construct a plasmid capable of expressing more transglutaminase than pIL6TG1, and a modification was made to increase the translation efficiency of the transglutaminase gene in E. coli . The modification involved substituting a portion of the DNA base sequence of the natural transglutaminase gene with chemically synthesized DNA to alter the base sequence without changing the coded amino acid sequence, and designing it so that the transglutaminase gene might yield a more efficient expression with E. coli . That is, as shown in Fig. 4, chemically synthesized DNA fragments designed to include a region coding for the section of transglutaminase from the amino terminal methionine to the 32nd amino acid, leucine (selecting codons preferred in E. coli or codons containing AT rich ones ), and a consensus SD (Shine-Dalgarno) sequence (5'-TAAGGAGGT-3') upstream therefrom were prepared (Sequence ID Nos. 12-19 of the sequence list), with the intention of incorporating them into the natural transglutaminase gene, according to the procedure described below. Eight DNA oligomers (Sequence ID Nos. 12-19 of the sequence list) for construction of the chemically synthesized DNA fragment named DNA-1 were synthesized with a DNA synthesizer (manufactured by A.B.I.). These oligomers were combined and linked using a conventional, publicly known method, that is, annealing and T4DNA ligase, to prepare the chemically synthesized DNA-1. Next, the DNA fragments were cloned in pUC19 digested with restriction enzymes Eco RI and Hin dIII, to construct pFTGN6 (Fig. 5). Also, this plasmid was used for verification of the DNA base sequence, confirming that the prepared DNA had the intended sequence. Plasmid pFTGN6 was digested with restriction enzymes Cla I and Hin dIII, and was further treated with restriction enzyme Hae II, to yield DNA fragment C (approximately 110 base pairs) having Cla I and Hae II cleavage termini (Fig. 6). On the other hand, plasmid pSLTG5 which includes cDNA coding for Pagrus major transglutaminase was treated with Eco RI, Hae II and Nco I to obtain a DNA fragment (DNA fragment B) of approximately 1.44 kbp (kilobase pairs), which was the major part of transglutaminase cDNA (Fig. 6). Expression vector pT13sNco (listed in J. Biochem. , 104 , 30-34, 1988) possessing the tryptophan promoter and trpA terminator was digested with Nco I and Bam HI, and both of the cleavage termini were made blunt with Klenow enzyme, after which a large DNA fragment was obtained. This was further self-ligated with T4DNA ligase to obtain pTTNco. Next, this pTTNco was digested with Cla I and Nco I, after which the cleavage termini were dephosphorylated with alkaline phosphatase to prepare a large DNA fragment (DNA fragment A) possessing a tryptophan promoter and a terminator (Fig. 6). Each of the DNA fragments, A, B and C was ligated with T4DNA ligase to construct plasmid pTTG1 (Fig. 7). For greater clarity, DNA fragment B represented by an outlined bar in Fig. 6 is represented by a solid bar in Figs. 7 and 8. Next, the constructed plasmid pTTG1 was treated with Bam HI, and the cleavaged termini were made blunt with Klenow enzyme, after which it was digested with Sac I to obtain the large DNA fragment shown in Fig. 8. Also, pSLTG5 was treated with restriction enzymes Sac I and Eco RV to prepare a small DNA fragment. These DNA fragments were ligated with T4DNA ligase to construct expression plasmid pTTG2-22 (Fig. 8). Expression plasmid pTTG2-22 was then introduced into E. coli HB101 using a publicly known method to prepare a transformant, Escherichia coli HB101/pTTG2-22, (AJ12742). AJ127242 is deposited as FERM BP-4117. A colony of the transformant obtained was applied onto an agar plate containing 200 µg/ml of ampicillin, and cultured at 30°C overnight, after which approximately 2 cm 2 of the lawn of growing cells from the plate were inoculated into a Sakaguchi flask containing 100 ml of an M9 casamino acid culture medium supplemented with 2% glucose, 200 µg/ml of leucine, 200 µg/ml of proline, 2.0 µg/ml of thiamine-HCl, and 200 µg/ml of ampicillin. The mixture was cultured at 30°C for about 16 hours to collect the cells. A supernatant from crushed cells was prepared from the collected cells in the same manner as in Example 3. Also, another supernatant was prepared by centrifugation of the crushed cells in the same manner from E. coli possessing a plasmid without transglutaminase cDNA ( E. coli HB101/pTTNco). The transglutaminase activity of each of the supernatants (50 µl) was verified in the same manner as in Example 3, according to an activity detection method which measures the change in fluorescence intensity (fluorescence intensity at 480 nm with 350 nm wavelength exciting light) due to bonding of monodansyl cadaverine with dimethylated casein (Table 2). The results clearly show that transglutaminase activity was present in the cell extract of E. coli which possesses an expression plasmid (pTTG2-22) having transglutaminase cDNA obtained in the example described above. It became obvious from this that the cDNA we obtained codes for transglutaminase. Strain TG cDNA Relative fluorescence intensity pTTNco/HB101 absent 21 pTTG2-22/HB101 present 910 Note: TGcDNA = transglutaminase cDNA Next, it was verified whether or not the above mentioned cell extract solution could gelatinize the myosin B solution derived from Alaska pollack, Theragra chalcogramma. 1.0 ml of an Alaska pollack-derived myosin B solution (approx. 6 mg/ml) was used as the substrate, and four samples were prepared, 1) 470 µl of 50 mM CaCl 2 and 100 µl of E. coli raw extract solution, for which the above mentioned transglutaminase activity was detected, were added, 2) 470 µl of 50 mM CaCl 2 was added, 3) 100 µl of E. coli raw extract solution, for which the above mentioned transglutaminase activity was detected, was added, 4) nothing was added. The samples were prepared, stirred and allowed to stand at room temperature for about 16 hours. The gelation of myosin B was judged by whether the reaction contents dripped or were hardened, when the test tube functioning as the reaction container was inverted. The results, shown in Table 3, indicated gelation in the presence of calcium chloride only in the sample to which addition was made of the E. coli extract which exhibited transglutaminase activity, proving that the cDNA acquired according to the present invention was clearly the gene which codes for transglutaminase. TG added TG not added Ca present Ca absent Ca present Ca absent Gelation of myosin B + - - - Note: TG : cell extract exhibiting transglutaminase activity Ca : calcium chloride + : gelatinized - : not gelatinized 5. Construction of plasmid pYSTG1 which expresses the Pagrus major transglutaminase gene, and its introduction into S. cerevisiae and verification of physiological activity of TGase produced by the transformant Plasmid pSLTG5 including cDNA which codes for Pagrus major transglutaminase was treated with restriction enzymes Eco RI and Xba I to obtain a DNA fragment of approximately 2.5 kbp (kilobase pairs) having transglutaminase cDNA. On the other hand, pYES2 (Invitrogen Co.), which is capable of using a promoter for GAL1 , a gene which codes for galactokinase, for the expression of foreign genes was used as the expression vector for S. cerevisiae . This was treated with the same restriction enzymes Eco RI and Xb aI to prepare a DNA fragment of approximately 5.8 kbp. The two above mentioned DNA fragments were ligated in a ligation reaction with T4DNA ligase according to a conventional method, and the product was introduced into an E. coli HB101 competent cell (manufactured by Takara shuzo Co.) according to a convention method. Selection of the transformant was done using an L-agar plate containing antibiotic ampicillin at a concentration of 100 µg/ml. Next, individual 6 strains were picked up from the cultured E. coli colonies using a sterilized toothpick, and each was transferred to a separate 3 ml L-culture medium containing 100 µg/ml of ampicillin, and shake culturing was effected at 30°C for 16 hours. Plasmid DNA was prepared from 2 ml of each of the culture using the alkaline SDS method, and the pattern of cleavage due to restriction enzymes was analyzed by agarose gel electrophoresis. This indicated that plasmids obtained from 4 of the strains were the desired one, and it was named pYSTG1. Further, the DNA base sequence was analyzed for the junction regions at the time of construction of the plasmid, verifying that the base sequences were correct. The pYSTG1 constructed as described above was then introduced into a yeast, Saccharomyces cerevisiae INVSC2 strain (MATα , his3-Δ200, ura3-167 ), according to the yeast transformation method using the alkaline cation method (manufactured by Bio101, purchased from Funakoshi Inc.). A YNB culture medium (composition: 0.67% yeast nitrogen base w/o amino acids (Difco Co.), 2% glucose, 2% agar) containing 20 mg/l of histidine was used as the selection plate. In this manner a transformant, Saccharomyces cerevisiae INVSC2/pYSTG1, (AJ14679) was obtained. AJ14679 is deposited as FERM BP-4085. The transformant yeast grown on the above mentioned YNB culture medium plate containing 20 mg/l of histidine was inoculated into 100 ml of a YPD culture medium (composition: 1% yeast extract, 2% bactopeptone, 2% glucose), and the mixture was cultured at 30°C for a day and a night in shaking. This was then centrifuged to collect the cells which were washed with 1% yeast extract, after which they were suspended in 10 ml of the same solution. Next, 5 ml, a half of the suspension, was added to 95 ml of a culture medium composed of 1% yeast extract, 2% bactopeptone and 2% galactose, and this was cultured at 30°C for 18 hours in shaking. Recombinant yeast was cultured in a galactose-containing culture medium to induce transcription from GAL1 promoter. Also, the remaining 5 ml of the suspension mentioned above was inoculated in the same manner into 95 ml of a liquid YPD culture medium, and culturing was done under conditions which did not induce transcription from GAL1 promoter. On the other hand, a host yeast INVSC2 strain not possessing the plasmid was also grown on another YPD culture plate, and inoculated in the same manner into 100 ml of a liquid YPD culture medium and cultured at 30°C. The above described procedures were then followed, and 5 ml of the obtained suspension was inoculated into 95 ml of the liquid YPD culture medium and cultured. Preparation of the sample for measurement of transglutaminase activity was done in the following manner. Yeast which had been cultured in 100 ml of a culture medium were centrifuged for the collection of cells to which 15 ml of a 20 mM Tris-HCl buffer solution (pH 7.5) containing 30 mM sodium chloride were added to suspended the cells. To the suspension, 0.25 ml of 0.5 M EDTA was added and stirred, after which an almost equal volume of glass beads (diameter 0.75 mm) were added to the suspension, and the mixture was stirred vigorously for 4 minutes. After this, centrifugation was done at 6000 rpm for 10 minutes, the insolubles were removed, and the supernatant thereof was used as a sample for measurement of transglutaminase activity. The transglutaminase activity of the supernatants (50 µl or 150 µl) from each of the disrupted cell solutions was verified in the same manner as in Example 3 described above, according to an activity detection method which measures the change in fluorescence intensity (fluorescence intensity at 480 nm with 350 nm wavelength exciting light) due to bonding of monodansyl cadaverine with dimethylated casein (Table 4). Here, the fluorescence intensity was treated as zero when the disrupted cell solution of yeast INVSC2 strain with no plasmid was added to the solution for the activity measurement. This result clearly showed that transglutaminase activity was present in the disrupted cell extract solution of the yeast which possessed the expression plasmid (pYSTG1) having transglutaminase cDNA obtained in Example 1 described above, under the induced condition of transcription from GAL1 promoter. Also, when EDTA was pre-added to the enzyme reaction solution and calcium ion was removed, there was, as expected, no detection of transglutaminase activity. Based on this, it was further proved that the cDNA which we obtained was which codes for transglutaminase depending on calcium ion. 6. DNA fragment containing a gene which codes for transglutaminase of flounder (illustrative) Using polytron and a teflon homogenizer, 1.5 g of the liver from flounder was crushed in a solution (20 ml) of 4 M guanidine thiocyanate and 1% beta-mercaptoethanol. After 0.5% sodium laurylsarcosinate was added to and dissolved in the resulting cell suspension, the obtained solution was passed through a 23-gauge hypodermic needle 8 times to fragment the chromosomal DNA. Next, the solution was centrifuged at 4°C, 1000 rpm for 20 minutes and the supernatant obtained. The complete RNA was further purified by a conventional method, through CsCl density gradient centrifugation of the supernatant (Sambrook et al., Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press (1988)). The amount of the complete RNA obtained was 4.7 mg. Of this, 1.6 mg was subjected to an mRNA purifying kit (Clontech) using an oligo(dT)-cellulose column, and approximately 23 microgram of a purified mRNA molecule was obtained. Of the obtained mRNA, 4.4 microgram was used as a template for cDNA synthesis. A random primer was used for cDNA synthesis, and a Time Saver cDNA synthesis kit (Pharmacia) was used to synthesize a double-stranded cDNA. The obtained cDNA was then inserted into a lambda-phage vector-lambdaZapII (Stratagene) at its restriction enzyme site Eco RI, after which a GIGAPACK II GOLD (Stratagene) packaging kit was used to prepare and acquire a cDNA library of flounder incorporated in the phage protein. The titer of this library was 2.0 x 10 5 pfu/microgram vector. Host cells XL1-Blue were infected with 2.2 x 10 5 pfu of phage from said cDNA library of flounder, after which they were spread onto 11 agar plates of diameter 150 mm at 2 x 10 4 pfu per plate. The cells were cultured at 37°C for about 6 hours, and then the phage plaques formed on the plates were transferred on a nylon membrane (Hibond-N, manufactured by Amersham). Next, the thus transcribed nylon membrane was treated with an alkali to denature the bound DNAs, neutralized and washed. Then, the membrane was treated at 80°C for 2.5 hours to immobilize the DNA on the membrane. Prehybridization of the obtained nylon membrane was then effected at 42°C for 2 hours, followed by hybridization at 42°C for 16 hours. The composition of the prehybridization solution was 6 x SSC (composition of 1 x SSC: 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 5 x Denhardt's solution (composition of 1 x Denhardt's solution: 0.02% BSA, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone), 20% formamide, 100 microgram/ml of herring testis DNA and 0.1% SDS. Also, the DNA probe used for the hybridization was the DNA fragment of about 300 bp of a cDNA of Pagrus major liver transglutaminase having Sequence No. 4 of the sequence list, the DNA fragment being able to code for the region containing the amino acid residues near to the active center and being able to be cleaved with restriction enzymes Cla I and Bam HI and having been random-labeled with [alpha-32P] dCTP. The candidate strains for the positive clones obtained by this screening were further subjected to second and third screening to finally obtain 10 positive clones. The infected cells maintaining the above mentioned 10 positive clones were then infected with helper phage (R408) to transform the cDNA derived from each of the positive clones into a form incorporated into phagemid vector pBluescriptSK(-). The length of the inserted cDNA of each of the 5 clones (named pFLTG10, 12, 16, 17, 21, respectively) of these clones was measured, from which the restriction enzyme cleavage map was constructed and the cDNA base sequences at the 5' end and the 3' end were sequenced. For the base sequencing, used was a fluorescent primer cycle sequencing kid (A.B.I.). As a result, the pFLTG21 was found to be a cDNA fragment of coding for the center part of a transglutaminase gene. Next, for the purpose of obtaining a clone capable of coding for the C terminal region of transglutaminase, which are not in the preceding 5 clones, the above-mentioned flounder cDNA library was again screened in the manner as mentioned below. As a DNA probe for the screening, used were a DNA fragment of about 300 bp capable of being cleaved out from clone pFLTG21 with restriction enzyme Eco RI and a DNA fragment of about 500 bp capable of being cleaved out from clone pFLTG17 with restriction enzymes Sal I and Pst I, the both fragments being random-labeled with [alpha-32P] dCTP. The other conditions were same as those mentioned above. As a result, a positive clone was obtained by the present screening, and finally 10 positive clones were obtained after second and third screenings. Of the preceding 10 positive clones, the vector of each of 4 cDNA clones was converted into pBluescript SK-, and the relationship between the inserted cDNA's was analyzed. The four clones were named pFLTG44, 51, 55 and 63, respectively. Further, for obtaining a clone capable of coding for the N terminal region of transglutaminase, a flounder cDNA library was newly prepared, using a synthesized DNA primer as formed on the basis of the base sequence of the inserted cDNA 5' end of pFLTG12 (the primer was composed of 19 bases, having a sequence of 5'-ACACTGCCGGTCCATCGAA-3'). As a template for synthesis of the cDNA, used was 2 microgram of the mRNA sample described above. The titer of the library obtained here was 1.5 x 10 4 pfu/microgram vector. Next, host E. coli cells XL1-Blue were infected with 6 x 103 pfu of phage from said cDNA library, and then the screening was carried out by the method mentioned above. As the probe for the hybridization, used were a DNA fragment of about 300 bp capable of being cleaved from the preceding clone pFLTG21 with restriction enzyme Eco RI, and a DNA fragment of about 500 bp capable of being cleaved from pFLTG17 with restriction enzymes Sal I and Pst I, the both fragments being random-labeled with [alpha-32P] dCTP. The candidate strains for the positive clones obtained by this screening were further subjected to second and third screening to finally obtain one positive cDNA clone. The clone was converted into pBluescript SK- by the method mentioned above, and the clone was named pFLTG60. Next, the length of the inserted cDNA of the clone was measured, the restriction enzyme map was constructed, and the cDNA base sequences of the 5' end and 3' end regions were sequenced. Of the thus obtained and sequenced 10 cDNA clones, the base sequence from the restriction enzyme Sal I site to the 3' end of the inserted cDNA in pFLTG17, and the base sequence of the inserted cDNA fragment in each of pFLTG21, 55, 60 and 63 were sequenced. As a result, the DNA sequences of SEQ ID NO: 45 and NO: 47 in the Sequence Listing were clarified. The difference between the two base sequences resides in the difference in the 1854th base. But the change of the base does not change the translated amino acid residue. The amino acid sequences to be translated from the base sequences are shown as SEQ ID NOS: 43 and 44. In addition, the relationship between the clones is shown in Fig. 11. An E. coli strain (AJ 12798) of E. coli XLI-Blue/pFLTG21 having plasmid pFLTG21 containing a part of the flounder-derived transglutaminase cDNA fragment (SEQ ID NO:45) obtained in the manner as above has been deposited in Fermentation Research Institute of Japan as FRI Deposition No. 4154 (FERM BP-4154); an E. coli strain (AJ 12799) of E. coli XLI-Blue/pFLTG55 having plasmid pFLTG55 as FRI Deposition No. 4155 (FERM BP-4155); an E. coli strain (AJ 12800) of E. coli XLI-Blue/pFLTG60 having plasmid pFLTG60 as FRI Deposition No. 4156 (FERM BP-4156); an E. coli strain (AJ 12801) of E. coli XLI-Blue/pFLTG63 having plasmid pFLTG63 as FRI Deposition No. 4157 (FERM BP-4157); and an E. coli strain (AJ 12797) of E. coli XLI-Blue/pFLTG17S having plasmid pFLTG17S having a cDNA clone fragment of the downstream region from restriction enzyme Sal I of the cDNA fragment of plasmid pFLTG17 as FRI Deposition No. 4153 (FERM BP-4153). Each plasmid having cDNA fragment coding for transglutaminase derived from Paralichthys olivaceus are shown in Fig. 12. The respective cDNA fragments thus obtained in the manner as mentioned above may easily be converted into one DNA fragment completely containing the coding region of transglutaminase by a known method. Plasmid pFLTG17S was digested with Pst I to prepare a large fragment containing cDNA segment. Similarly, pFLTG63 was digested with Pst I to prepare a DNA fragment coding for the C-terminal region of the transglutaminase. Both DNA fragment as mentioned above were ligated with T4 DNA ligase to construct pFLTG1-C in which the reading frame of the C-terminal region of transglutaminase was made to be conjugative. On the other hand, pFLTG21 was digested with Bgl II and Pst I to prepare a large fragment. Similarly, pFLTG60 was treated with Bgl II and Pst I to prepare a DNA fragment coding for the N-terminal region of the transglutaminase. Both DNA fragment as mentioned above were ligated with T4DNA ligase to construct pFLTG1-N in which the reading frame of the N-terminal region of the transglutaminase was made to be conjugative. After pFLTG1-N was digested with Eco R I, the vector DNA of which both ends were dephosphorylated was ligated to the cDNA fragment derived from pFLTG1-N, and then pFLTG2-N in which cDNA fragment was inserted into the vector in the opposite derection in constrast with the directionof cDNA fragment in pFLTG1-N. Then, pFLTG2-N was digested with Sal I to prepare cDNA fragment coding for the N-terminal region of the transglutaminase. The cDNA fragment was incorporated into the restriction site Sal I in pFLTG1-C digested with Sal I to construct one cDNA fragment completely containing the coding region of the transglutaminase in the vector DNA. On the other hand, transformation of E. coli strain recBC, sbcA with a single-stranded plasmid DNA having two cDNA fragments each having a duplicated cDNA region (for example, cDNA fragments on the respective plasmids of pFLTG60 and pFLTG21; pFLTG21 and pFLTG17; pFLTG17 and pFLTG63) at both ends brings about extremely easily recombination at the duplicated region in these cDNA fragments due to the recombination mechanism in the host E. coli strain, resulting in construction of a successively continued cDNA fragment. Repeating the process, the intended cDNA of a complete length is obtained. Utilizing the recombination mechanism of the kind, various chimera genes are constructed(Ogawa et al., Journal of Molecular Biology, 226 651-660 1992). Also we, the present inventors investigated the translated amino acid sequence of each transglutaminase cDNA derived from Pagrus major , Theragra Chalcogramma, and Paralichthys olivaceus . As a result, it was found to be some consensus amino acid sequences among the amino acid sequences of transglutaminase derived from fish. These consensus amino acid sequences were shown as SEQ ID NOS: 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 and 64. Xaa indicates a nonspecific amino acid residue. [7. Investigation as to whether or not many other fishes of different kinds would have a gene homologous to the obtained Pagrus major transglutaminase cDNA] (illustrative) We the present inventors investigated as to whether or not a gene which is extremely highly homologous to the Pagrus major- derived transglutaminase gene as obtained by us in the previous example would exist in any other fishes of different kinds. As test samples, used were the livers of horse mackerel, young yellowtail, sardine, Pacific saury, mackerel, bonito and salmon and the ovary of globefish; and as a negative control sample, used was the chromosome of Bacillus subtilis. About 3 g of the tissues of the respective fishes were cut into fine pieces, and 30 ml of an ice-cooled TN buffer (20 mM tris-HCl buffer (7.5) containing 0.1 M sodium chloride, as its composition) was added thereto and crushed with a teflon homogenizer. The sample suspension was put in a centrifugal tube and subjected to centrifugation with a cooling centrifuger at 5°C and at 1,500 rpm for 5 minutes to obtain a precipitated fraction. To this was added 5 ml of an ice-cooled TNE buffer (TN buffer containing 1 mM EDTA, as its composition) and well suspended. Then, 15 ml of the ice-cooled TNE buffer was further added thereto and mixed. Afterwards, 1 ml of 10% SDS was added thereto and shaken at room temperature for 30 minutes, then 100 microliter of 20 mg/ml Protease K solution was added thereto and reacted overnight at 50°C. After the reaction, the aqueous solution of each sample was subjected to phenol treatment, phenol-chloroform treatment and chloroform treatment for removal of proteins therefrom. Afterwards, 1/50 volume of 5 M sodium chloride and 2.5 times volume of ethanol were added to each sample so as to precipitate the nucleic acid. This was recovered and finally dissolved in 1 ml of a TE buffer (10 mM tris-HCl buffer (pH 7.6) containing 1 mM EDTA, as its composition). Next, about 10 microgram of the DNA of each sample was digested with 200 units of restriction enzyme Hin dIII and subjected to electrophoresis using 1% agarose gel. The gel was stained with ethidium bromide to ascertain that the amount of the migrated DNA of each sample was almost constant. Then, the gel was dipped in 0.25 N hydrochloric acid and subsequently treated with a 0.4 N sodium hydroxide solution containing 0.6 M sodium chloride. Next, the gel was neutralized with a 0.5 M tris-HCl buffer (pH 7.5) containing 1.5 M sodium chloride, and the nucleic acid in the gel was transcribed to a nylon membrane (Gene Screen Plus) with 10 x SCC (composition: 1.5 M sodium chloride, 0.15 M trisodium citrate). The membrane with the nucleic acid as adsorbed thereto was treated with 0.4 N sodium hydroxide containing 0.6 M sodium chloride, then with a 0.5 M tris-HCl buffer (pH 7.5) containing 1.5 M sodium chloride, and thereafter dipped in a 2 x SCC solution. Afterwards, the membrane was left at room temperature for 30 minutes and then dried at 80°C for 2 hours. The thus obtained nylon membrane was subjected to prehybridization at 65°C for 3 hours and then to hybridization at 60°C for 16 hours. The composition of the prehybridization solution was 5 x SSC (composition of 1 x SCC: 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 1 x Denhardt's solution (composition of 1 x Denhardt's solution: 0.02% BSA, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone) and 0.1% SDS. The composition of the hybridization solution comprised 0.75 M sodium chloride, 20 mM tris-HCl (pH 8.0), 0.25 mM EDTA, 1% SDS, 1 x Denhardt's solution and 50 microgram/ml of E. coli genom solution. The DNA probe as prepared in the manner mentioned below was used in the form of having a concentration of 2 x 10 5 cpm/ml. As the DNA probe, used was a DNA fragment as radio isotope-labeled with a random primer, using guinea pig transglutaminase cDNA fragment and the Pagrus major transglutaminase cDNA fragment as obtained by us each as a template. As the guinea pig transglutaminase cDNA fragment, used was one in which the plasmid pKTG1 (Ikura et al., Eur. J. Biochem., Vol 187, 705-711, 1990) had been treated with restriction enzyme Stu I. For the Pagrus major transglutaminase cDNA, the obtained cDNA clone pSLTG5 was cleaved with restriction enzymes Apa I and Sac I, and the resulting transglutaminase cDNA fragment was used as a template. The membrane which had been subjected to the hybridization mentioned above was washed with 0.1 x SCC and 0.1% SDS solution at 60°C, dried and then subjected to autoradiography. As a result, it was found that the guinea pig-derived DNA probe did not hybridize to the nucleic acid of all the test samples under the condition of this experiment; while the Pagrus major -derived DNA probe did not hybridize to the chromosomal DNA of B. subtilis at all but strongly hybridized to the nucleic acids derived from horse mackerel, bonito, mackerel, young yellowtail and globefish and to, though weakly, those derived from sardine, Pacific saury and salmon. From the above-mentioned facts, the existence of a gene having a high homology to the transglutaminase gene as obtained by us in other fishes of different kinds was verified for the first time; and it was also verified for the first time that a transglutaminase gene may also be obtained with extreme ease even from other fishes of different kinds than Pagrus major , Alaska pollack, Theragra chalogramma, and flounder, Paralichthys olivaceus , by the use of the transglutaminase as obtained by us as a DNA probe. [8. Analysis of partial amino acid sequence of Alaska pollack liver transglutaminase] (illustrative) In order to show the fact that the Alaska pollack-derived transglutaminase gene as obtained in the manner mentioned above is one to actually express a transglutaminase enzyme in an Alaska pollack, the natural enzyme was purified and the structure thereof was clarified. The transglutaminase activity of the enzyme was verified according to an activity detection method which measures the change in Fluorescence intensity due to bonding of monodansylcadaverine with dimethylated casein as an index, in accordance with the activity detecting method mentioned above. 30 ml of a 20 mM tris-HCl buffer (pH 8.3) containing 10 mM NaCl, 5 mM EDTA and 2 mM dithiothreitol was added to 15 g of Alaska pollack liver and crushed with a homogenizer. The thus suspension was centrifuged at 4°C, 3,000 rpm for 10 minutes (Hitachi's Himac CR 20B2, with rotor RPR20-2). Then, the supernatant was further centrifuged at 4°C, at 37,000 rpm for one hour (Hitachi's 70P-72, with rotor RP-70T). The supernatant was filtered through a 0.45 micrometer-filter (GL Science's GL Chromatodisc) to obtain 24 ml of a crude extract. The protein concentration of the extract was measured with a BioRad's protein assay kit to be about 8.6 mg/ml. Using 5 microliter of the crude extract, the transglutaminase activity thereof was determined to have a total activity of 849 units. Thus, the relative activity of it was 4.10 units/mg protein. Next, the crude extract was passed through a Q-Sepharose column (Pharmacia; diameter 1.6 cm x 10 cm) as equilibrated with the same buffer, whereupon the ion exchanger of the column adsorbed the transglutaminase. Then, NaCl concentration gradient elution of the column was effected to give a fraction having a transglutaminase activity at the NaCl concentration of about 100 mM. The thus obtained transglutaminase-active fraction (10 ml) was subjected to dialysis to the same buffer overnight, again passed through the Q-Sepharose column and subjected to elution under the same condition to obtain 9.5 ml of a fraction having a transglutaminase-activity. The protein concentration of the active fraction was about 0.73 mg/ml. The total transglutaminase activity of it was 249 units, and therefore the relative activity of it was 36.1 units/mg protein. Next, the thus obtained active fraction was subjected to dialysis overnight to a sodium acetate solution (pH 6.45) containing 50 mM NaCl, 2 mM EDTA and 0.5 mM dithiothreitol and applied to through an S-Sepharose column (Pharmacia: diameter 1.6 cm x 10 cm) as equilibrated with the same buffer, whereupon the column adsorbed the transglutaminase. Then, NaCl concentration gradient elution of the column was effected to give a fraction (6.0 ml) having a transglutaminase activity at the NaCl concentration of about 200 mM. The protein concentration of the active fraction was about 56 microgram/ml. The total transglutaminase activity of it was 201 units, and therefore the relative activity of it was 591.2 units/mg protein. In the fraction, only a protein showing a single band of a molecular weight of about 77,000 on SDS-PAGE exited, and thus an Alaska pollack-derived transglutaminase was purified and obtained. The relative activity of the purified fraction was 143 times as large as that of the crude extract; and the recovery yield of the former was 23.7%. a) Electrophoresis Assay 30 microliter of a purified transglutaminase solution was added with the same amount of a 0.125 M tris-HCl buffer (pH 6.8) containing 10% mercaptoethanol, 4% SDS, 20% glycerin and 0.002% bromophenol blue, and heated in a boiling bath for one minute to prepare a sample for electrophoresis. 40 microliter of the sample was applied to a prepared 5 to 20% polyacrylamide gel (ATTO) and subjected to electrophoresis with a 0.025 M tris-glycine buffer containing 0.1% SDS for about 2 hours at 40 mA. After completion of the process, the migrated sample was stained overnight with a 0.12% Coomassie brilliant blue solution containing 50% methanol and 7% acetic acid and then decolored with a 7% acetic acid solution containing 50% methanol. As a result, a single band was obtained at a molecular weight of about 77,000. b) Partial amino acid sequence of Alaska pollack liver-derived transglutaminase About 4 ml of the S-Sepharose fraction containing about 80 microgram of the purified transglutaminase was put in a dialytic tube and subjected to dialysis to a 5 mM tris-HCl buffer (pH 8.3) containing 0.001 mM EDTA for 6 hours, then again to dialysis to the same solution, whereby the alkali metal ions were removed from the transglutaminase product. This was dried by centrifugal concentration, 0.8 ml of distilled water was added thereto and stirred at 37°C for 30 minutes so that the product was again dissolved in the water. To this was added 16 microgram of trypsin (by Sigma; 11,700 units/mg) and reacted at 37°C for 12 hours, whereby this was fragmented into peptide fragments. The reaction was terminated by adding one drop of formic acid thereto. Next, the reaction liquid was applied to a reverse phase HPLC (Inertsil Prep-ODS; diameter 6.0 mm x 250 mm; by GL Science), using a solvent of 0.05% TFA (trifluoroacetic acid), whereupon the respective peptide fragments were separated and collected by acetonitrile concentration gradient elution. The thus obtained peptide fragments were applied to a protein sequencer (MilliGen Biosearch; 6400/6600) to sequence the amino acid sequence of them. As a result, the following sequences were obtained. They were Xaa-Ala-Gly-Gly-Ser-Gly-Asp; Trp-Trp-Leu-His-Gln-Gln-Ser; Met-Tyr-Leu-Leu-Phe-Asn-Pro; Trp-Gln-Glu-Pro-Tyr-Thr-Gly-Gly; Phe-Asp-Val-Pro-Phe-Val-Phe-Ala-Glu-Val-Asn-Ala-Asp; Ser-Xaa-Tyr-Ser-Asn-Glu. (SEQ ID NO:20, 21, 22, 23, 24, and 25)) Xaa indicates an unidentified amino acid residue. The above-mentioned six amino acid sequences completely correspond to a part of the amino acid sequence (SEQ ID NO: 6, 7) which is presumed from the base sequence of the cDNA already obtained by us. The fact indicated that the cDNA obtained by us was just one which had been expressed in the body of Alaska pollack and which coded for the active transglutaminase. [9. Analysis of partial amino acid sequence of Pagrus major liver transglutaminase] On the other hand, in order to show the fact that the Pagrus major -derived transglutaminase gene as obtained in the manner mentioned above is one to actually express a transglutaminase enzyme in a Pagrus major , the natural enzyme was purified and the structure thereof was clarified. Like the case of the previous Alaska pollack-derived enzyme, the transglutaminase activity of the enzyme of the present case verified according to an activity detection method which measures the change in Fluorescence intesity due to bonding of monodansylcadaverine with dimethylated casein as an index, in accordance with the activity detecting method mentioned above. 46 ml of a 20 mM tris-HCl buffer (pH 8.3) containing 10 mM NaCl, 5 mM EDTA and 2 mM dithiothreitol was added to 20 g of Pagrus major liver and crushed with a homogenizer. The thus suspension was put in a centrifugal tube and applied to a centrifuger (Hitachi's 70P-72, with rotor RPRP-65T) at 4°C, 50,000 rpm for 45 minutes. Then, the supernatant part was passed through a 0.45 micrometer-filter (Advantic DISMIC-25 disposable syringe filter unit) so that insoluble high polymer substances were removed. As a result, 30 ml of an extremely red-colored extract was obtained. Next, almost the same amount (30 ml) of an ice-cooled 5 mM tris-HCl buffer (pH 8.3) was added to the extract so that the ionic strength of the resulting solution was lowered. This was a crude extract of Pagrus major liver (60 ml). The protein concentration of the extract was measured with a BioRad's protein assay kit to be about 8.4 mg/ml. Using 5 micrometer of the crude extract, the transglutaminase activity thereof was determined to have a total activity of 2088 units. Thus, the relative activity of it was 4.14 units/mg protein. Next, the crude extract was passed through a DEAE-Sephacel column (Pharmacia; diameter 2.6 cm x 11 cm) as equilibrated with a 10 mM tris-HCl buffer (pH 8.3) containing 5 mM NaCl, 2.5 mM EDTA and 0.5 mM dithiothreitol, whereupon the ion exchanger of the column was found to adsorb the transglutaminase. NaCl concentration gradient elution of the column was effected to give a fraction having a transglutaminase activity at the NaCl concentration of about 100 mM. The fraction was a DEAE fraction (about 59 ml). The protein concentration of the active fraction was about 145 microgram/ml. The total transglutaminase activity of it was 1045 units, and therefore the relative activity of it was 122 units/mg protein. The transglutaminase-active fraction thus fractionated with the DEAE-Sephacel resin was put in a dialytic tube and subjected to dialysis overnight to a 20 mM sodium acetate buffer (pH 6.25) containing 2 mM EDTA and 0.5 mM dithiothreitol. Next, the product was passed through a CM-Sepharose column (Pharmacia; diameter 1.6 cm x 10 cm) as equilibrated with the same buffer, whereupon the column adsorbed the transglutaminase. Then, NaCl concentration gradient elution of the column was effected to give a transglutaminase-active fraction at the NaCl concentration of about 200 mM. The fraction (about 35 ml) was obtained to be a CM fraction. The protein concentration of the active fraction was about 20 microgram/ml. The total transglutaminase activity of it was about 530.6 units, and therefore the relative activity of it was 758 units/mg protein. The transglutaminase-active fraction thus fractionated with the CM-Sepharose resin was again put in a dialytic tube and subjected to dialysis overnight to a 20 mM sodium acetate buffer (pH 6.45) containing 50 mM NaCl, 2 mM EDTA and 0.5 mM dithiothreitol so that the salt concentration in the transglutaminase fraction liquid was lowered. This was passed through a heparin-Sepharose column (Pharmacia; Hi-Trap affinity column; bed-volume 1 ml) as equilibrated with the same buffer, whereupon the resin adsorbed the transglutaminase. NaCl concentration gradient elution of the column was effected, whereupon the transglutaminase was eluted from the heparin column at the NaCl concentration of about 200 mM. This was obtained (about 12.5 ml). This was a heparin fraction. The protein concentration of the active fraction was about 32 microgram/ml. The total transglutaminase activity of it was about 290.5 units, and therefore the relative activity of it was 807 units/mg protein. The present heparin fraction was subjected to SDS-polyacrylamide gel electrophoresis and then the gel was stained with Coomassie brilliant blue, whereupon a single band as stained at only the position of a molecular weight of about 77,000 was identified. Thus, a Pagrus major liver-derived transglutaminase was purified and obtained. The relative activity of the thus obtained pure transglutaminase fraction was about 195 times as high as that of the crude extract and the recovery yield of the former was about 14%. The partial amino acid sequence of the Pagrus major liver-derived transglutaminase was analyzed. About 4 ml of the heparin fraction containing about 100 microgram of the purified transglutaminase was put in a dialytic tube and subjected to dialysis for 13 hours to a 20 mM tris-HCl buffer (pH 8.3) containing 0.1 mM EDTA and 0.01 mM dithiothreitol and then to a 20 mM tris-HCl buffer (pH 8.3) containing 0.001 mM EDTA, whereby the alkali metal ions in the transglutaminase enzyme product was removed. To this was added 480 mg of urea and treated at 37°C for 30 minutes. Then, 7.5 microgram (0.02 unit amidase activity) of lysyl endo-peptidase (Wako Pure Chemicals) was added thereto and enzymatically treated therewith at 37°C for further 12 hours so that the transglutaminase was fragmented to peptide fragments. After the treatment, 40 microliter of a 10% TFA (trifluoroacetic acid) solution was added to the reaction liquid and stirred, the final concentration of TFA being 0.1%. Next, the reaction liquid was applied to a reversed phase HPLC (Vydac's C4 column; diameter 4.6 mm x 250 mm), using a solvent of 0.1% TFA, for acetonitrile concentration gradient elution to separate the respective fragments, which were recovered. The thus obtained peptide fragments were applied to a protein sequencer (Applied Biosystems; 470A) and the amino acid sequence of each of them was analyzed with a sequence analyzer (Applied Biosystems; 120A). The results are listed in SEQ ID NOS:26 to 42 (See Sequence Listing). Xaa indicates an unidentified amino acid residue. These amino acid sequences are in the amino acid sequence (SEQ ID NOS: 2, 3) to be derived from the cDNA sequence obtained in the previous Example 1. The fact surely indicates that the cDNA as obtained herein codes for the enzyme of showing the transglutaminase activity as functioning in a living body of a Pagrus major . [10. Comparison of the enzymatic characteristics between guinea pig-derived transglutaminase and fish-derived transglutaminase] (illustrative) The enzymatic characteristic of fish-derived transglutaminase (hereinafter referred to as FTG) were compared with those of guinea pig (marmot)-derived transglutaminase (hereinafter referred to as MTG) and the difference between them was investigated. In particular, the industrial superiority of FTG to MTG was investigated by the comparison. a) Relative activity The enzymatic relative activity of the pure Alaska pollack transglutaminase as obtained in the previous example was compared with that of a commercial MTG by a fluorescent method. MTG samples used herein were one from Takara Shuzo and one from Sigma. Takara Shuzo's MTG had a purity of 95 %; and Sigma's MTG had the similar purity. The above-mentioned three transglutaminase products were prepared to have the same enzymatic concentration (as measured by Biorad's protein assay kid for the protein concentration), and the transglutaminase activity of each sample was measured at a pH value of 8.5 of being near to the respective optimum pH. As a result, it was found that the relative activity of FTG was 10 times as high as that of MTG (Takara Shuzo) and was 20 times as high as that of MTG (Sigma). The above-mentioned three transglutaminase products each having a controlled concentration were developed with SDS-PAGE, stained with Coomassie Brilliant Blue and applied to a densitometer (LKB; Ultro Scan XL Laser Densitometer) to determine the quantity of the transglutaminase of each sample product. As a result, it was found that the transglutaminase quantity in FTG was about 4 times as high as those of the other MTG's. From the fact, it was found that the transglutaminase relative activity of FTG by a fluorescent method was 2.5 to 5 times as high as that of MTG. As mentioned above, the relative activity of FTG is higher than that of MTG. Thus, in view of the industrial use of the enzyme, the amount of the FTG to be used for attaining expression of the same effect may be reduced lower than that of the MTG. Accordingly, the industrial advantage of FTG is noticeable because of the reduction of the cost of producing it. b) Thermal stability Next, FTG and MTG were compared with each other with respect to the easiness of thermal deactivation of them. The amount of the enzyme used for the test was such that would show the activity of the same degree. Each transglutaminase product was first put in a tris-HCl buffer (pH 8.5) (in the form of a solution comprising 250 microliter of 0.5 M tris-HCl buffer (pH 8.5), 80 microliter of 100 mM DTT, 37 microliter of 1 mM monodansylcadaverine and 1300 microliter of water as the composition) and treated at 0°C, 20°C, 25°C, 30°C, 37°C, 40°C, 42°C, 50°C or 60°C for 10 minutes, then cooled with ice for 3 minutes to stop the thermal treatment of the product. Next, 250 microliter of 10 mg/ml dimethylated casein solution and 500 microliter of 50 mM calcium chloride solution were added thereto and reacted at 37°C for 60 minutes. Afterwards, 100 microliter of 0.5 M EDTA was added to each of the reaction liquids so that the enzymatic reaction was stopped. The fluorescent intensity of each of the thus prepared reaction liquids was measured in the manner as mentioned above, whereby the thermal stability of the enzyme tested was determined. As a result, it was clarified that the temperature of treating FTG for giving the residual activity of 50% was lower than that of MTG by about 9°C, as shown in Fig. 13. The fact indicates that FTG is more easily deactivated than MTG. In combination with the result in the previous a), it is concluded that FTG has a higher enzymatic reactivity and may more easily be deactivated by mere heat treatment of the reaction product, than MTG. c) Reactivity with actomyosin Actomyosin (AM) was prepared in the manner mentioned below. First, about 60 ml of a 20 mM tris-HCl buffer (pH 7.5) containing 0.5 M sodium chloride was added to about 30 g of frozen surimi of Alaska pollack (SA grade product by Taiyo Fishery) and homogenized with Excellauto Homogenizer (manufactured by Nissei Industry). This was then subjected to centrifugation three times each at 10,000 rpm for 30 seconds, using Hitachi's Himac CR20B2 Model Centrifuger (with rotor of RPR20-2) so that insoluble substances were removed therefrom. The resulting supernatant was put in a dialytic tube (Seamless Cellulose Tubing, imported by Sanko Pure Chemicals) and subjected to dialysis to a 20 mM tris-HCl buffer (pH 7.5) containing 0.5 M sodium chloride, for 3 hours and then for 16 hours. Afterwards, the dialyzed liquid was subjected to centrifugation at 14,000 rpm for 60 minutes to obtain the supernatant. This was filtered through a cotton gauze cloth to prepare an actomyosin solution (about 27 ml). The protein concentration of the solution was measured with BioRad's Protein Assay Kit to be 26.1 mg/ml. Using the actomyosin as prepared in the manner mentioned above, MTG and FTG were compared with each other with respect to the action and effect thereof on polymerization of the myocin protein. Polymerization of myocin is said to be an index having a close relation to the "good taste" of marine paste products, including the elasticity displaying function of kamaboko (boiled fish paste product), from the result of the study (Nippon Suisan Gakkaishi 51 1559-1565 (1985)) and (Nippon Suisan Gakkaishi 56 125-132 (1990)). The actomyosin as prepared in the manner mentioned above was formed into a solution having a concentration of 10 mg/ml, using a 20 mM tris-HCl buffer (pH 7.5) containing 0.5 M sodium chloride, and one ml of this was put in a test tube (washed test tube Larbo, by Terumo; 15.5 x 100 mm). Plural test tubes each containing it were prepared. To each of them was added 200 microliter of 50 mM calcium chloride and stirred. Then, 200 microliter of a separately prepared FTG or MTG (both having the same activity as measured by a fluorescent activity measuring method) was added thereto and fully stirred. MTG was one produced by Sigma. After addition of each transglutaminase, it was reacted at 37°C for 15 minutes, 30 minutes, 45 minutes and 60 minutes. After the reaction, 100 microliter of the reaction solution was sampled from each test tube, and 100 microliter of a 20 mM tris-HCl buffer (pH 8.5) containing 8 M urea, 2% SDS and 2% beta-mercaptoethanol was added thereto so that the reaction was stopped. Next, 300 microliter of a 125 mM tris-HCl buffer (pH 6.8) containing 4% SDS, 10% beta-mercaptoethanol, 20% glycerin and 0.002% bromophenol blue was added thereto, and the sample was then heated at 100°C for one minute to give a sample for SDS-PAGE. 5 microliter of each of the thus prepared samples was applied to SDS-PAGE for electrophoresis, then stained with Coomassie Brilliant Blue, and the monomer amount of the myocin H chain was measured with a densitometer (Ultro Scan XL Laser Densitometer, by LKB). From this, the effect of the transglutaminase tested on the polymerization of the myocin protein was analyzed. The result is shown in Fig. 14, from which it was found that FTG could more rapidly polymerize the myocin protein than MTG. The fact further indicates that FTG is better than MTG also in application of the transglutaminase enzyme to marine paste products because of reduction of the manufacture cost. " Effect of the Invention In the past, the sources which could be used to supply transglutaminase have included actinomyces and guinea pigs, but the present invention provides a DNA fragment coding for a Pagrus major-derived transglutaminase which codes for a polypeptide expressing a function for the retention and reinforcement of the texture of traditional processed marine products such as boiled fish paste "kamaboko", etc., and also whose function in naturally occurring substances is known. By applying gene recombination technology to the Pagrus major transglutaminase gene obtained according to the present invention, mass production of transglutaminase is possible, and by applying said produced enzyme, the properties of edible protein may be altered and the foods may be nutritionally improved. Also, in addition to food products, this enzyme may be applied to pharmaceuticals and manufacture of chemical products. Brief Description of the Drawings Fig. 1 : A restriction enzyme map for plasmid pSLTG5 which possesses the acquired cDNA with a gene coding for Pagrus major transglutaminase. Fig. 2 : The correlation among cDNA clones which codes for Alaska pollack, Theragra chalcogramma, transglutaminase, and the restriction enzyme map for the cDNA. Fig. 3: A construction process of plasmid pIL6TG1 for the expression of Pagrus major transglutaminase. Fig. 4: A base sequence listing of chemically synthesized DNA-1. This shows the DNA base sequence which contains consensus SD (Shine-Dalgarno) sequence of E. coli and codes for the region from methionine at the amino terminus of Pagrus major transglutaminase to the 32nd amino acid, leucine. Fig. 5: A construction process of plasmid pFTGN6 for the construction of plasmid pTTG2-22 for the expression of Pagrus major transglutaminase. Fig. 6: An acquisition process of DNA fragments A, B and C for the construction of plasmid pTTG2-22 for the expression of Pagrus major transglutaminase. Fig. 7: A construction process for plasmid pTTG1. Fig. 8: A construction process for expression plasmid pTTG2-22 for Pagrus major transglutaminase. Fig. 9: A construction process of plasmid pYSTG1 for expression of Pagrus major transglutaminase cDNA in yeast. Fig. 10 shows the restriction emzyme cutting sites in cDNA clone coding for transglutaminase derived from Theragra chalcogramma muscule. Fig. 11 shows the restriction emzyme cutting sites in cDNA clone Paralichthys olivaceus liver. Fig. 12 shows a plasmid carrying a cDNA fragment coding for transglutaminase derived from Paralichthys olivaceus . Fig. 13 shows comparison of the thermal stability between Alaska pollack-derived transglutaminase (FTG) and guinea pig-derived transglutaminase (MTG); where o-o indicates the relative residual activity of FTG, and - indicates the relative residual activity of MTG. Fig. 14 shows comparison of the reactivity in polymerization of myocin H chain between Alaska pollack-derived transglutaminase (FTG) and guinea pig-derived transglutaminase (MTG); where - indicates the reactivity of FTG, - indicates that of MTG, and - indicates that of control (no enzyme). The DNA fragments provided by the present invention, and the peptides coded for by the respective DNAs are represented by the following sequences: Sequence Table SEQ ID NO:1 SEQUENCE LENGTH:25 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:2 SEQUENCE LENGTH:694 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:3 SEQUENCE LENGTH:695 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:4 SEQUENCE LENGTH:2085 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR MOLECULE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:1..2085 SEQUENCE DESCRIPTION SEQ ID NO:5 SEQUENCE LENGTH:2520 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR MOLECULE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:34..2121 SEQUENCE DESCRIPTION SEQ ID NO:6 SEQUENCE LENGTH:695 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:7 SEQUENCE LENGTH:696 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:8 SEQUENCE LENGTH:2088 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR MOLECULE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:1..2088 SEQUENCE DESCRIPTION SEQ ID NO:9 SEQUENCE LENGTH:2921 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR MOLECULE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:32..2122 SEQUENCE DESCRIPTION SEQ ID NO:10 SEQUENCE LENGTH:29 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA SEQUENCE DESCRIPTION SEQ ID NO:11 SEQUENCE LENGTH:8 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE SEQUENCE DESCRIPTION SEQ ID NO: 12 SEQUENCE LENGTH:30 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA FEATURE FEATURE KEY:RBS POSITION:15..23 SEQUENCE DESCRIPTION SEQ ID NO: 13 SEQUENCE LENGTH:30 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA FEATURE FEATURE KEY:CDS POSITION: 1..30 SEQUENCE DESCRIPTION SEQ ID NO: 14 SEQUENCE LENGTH:32 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA FEATURE FEATURE KEY:CDS POSITION:1..32 SEQUENCE DESCRIPTION SEQ ID NO:15 SEQUENCE LENGTH:33 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA FEATURE FEATURE KEY:CDS POSITION:1..33 SEQUENCE DESCRIPTION SEQ ID NO: 16 SEQUENCE LENGTH:30 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA SEQUENCE DESCRIPTION SEQ ID NO:17 SEQUENCE LENGTH:30 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA SEQUENCE DESCRIPTION SEQ ID NO:18 SEQUENCE LENGTH:32 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA SEQUENCE DESCRIPTION SEQ ID NO:19 SEQUENCE LENGTH:33 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:SINGLE TOPOLOGY:LINEAR MOLECULE TYPE:OTHER NUCLEIC ACID SYNTHETIC DNA SEQUENCE DESCRIPTION SEQ ID NO:20 SEQUENCE LENGTH:7 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Teragra chalcogramma TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:21 SEQUENCE LENGTH:7 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Teragra chalcogramma TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:22 SEQUENCE LENGTH:7 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Teragra chalcogramma TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:23 SEQUENCE LENGTH:8 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Teragra chalcogramma TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:24 SEQUENCE LENGTH:13 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Teragra chalcogramma TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:25 SEQUENCE LENGTH:6 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Teragra chalcogramina TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:26 SEQUENCE LENGTH:10 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:27 SEQUENCE LENGTH: SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:28 SEQUENCE LENGTH:9 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:29 SEQUENCE LENGTH:16 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:30 SEQUENCE LENGTH:18 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:31 SEQUENCE LENGTH:16 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:32 SEQUENCE LENGTH:14 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:33 SEQUENCE LENGTH:18 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:34 SEQUENCE LENGTH:15 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:35 SEQUENCE LENGTH:17 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:36 SEQUENCE LENGTH:9 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:37 SEQUENCE LENGTH:9 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:38 SEQUENCE LENGTH:18 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:39 SEQUENCE LENGTH:11 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:40 SEQUENCE LENGTH:10 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:41 SEQUENCE LENGTH:8 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:42 SEQUENCE LENGTH:11 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:Pagrus major TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:43 SEQUENCE LENGTH:687 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Paralichthys olivaceus TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID Neo:44 SEQUENCE LENGTH:688 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR SEQUENCE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Paralichthys olivaceus TISSUE TYPE:LIVER SEQUENCE DESCRIPTION SEQ ID NO:45 SEQUENCE LENGTH:2054 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR SEQUENCE TYPE:CDNA to mRNA ORIGINAL SOURCE ORGANISM:Paralichthys olivaceus TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:1..2054 SEQUENCE DESCRIPTION SEQ ID NO:46 SEQUENCE LENGTH:2148 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR SEQUENCE TYPE:CDNA to mRNA ORIGINAL SOURCE ORGANISM:Paralichthys olivaceus TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:26..2092 SEQUENCE DESCRIPTION SEQ ID NO:47 SEQUENCE LENGTH:2054 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR SEQUENCE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Paralichthys olivaceus TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:1..2054 SEQUENCE DESCRIPTION SEQ ID NO:48 SEQUENCE LENGTH:2148 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR SEQUENCE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Paralichthys olivaceus TISSUE TYPE:LIVER FEATURE FEATURE KEY:CDS POSITION:26..2092 SEQUENCE DESCRIPTION SEQ ID NO:49 SEQUENCE LENGTH:640 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:MUSCLE SEQUENCE DESCRIPTION SEQ ID NO:50 SEQUENCE LENGTH:641 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PROTEIN ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:MUSCLE SEQUENCE DESCRIPTION SEQ ID NO:51 SEQUENCE LENGTH:1921 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR MOLECULE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:MUSCLE FEATURE FEATURE KEY:CDS POSITION:1.. SEQUENCE DESCRIPTION SEQ ID NO:52 SEQUENCE LENGTH:1962 SEQUENCE TYPE:NUCLEIC ACID STRANDEDNESS:DOUBLE TOPOLOGY:LINEAR MOLECULE TYPE:cDNA to mRNA ORIGINAL SOURCE ORGANISM:Theragra chalcogramma TISSUE TYPE:MUSCLE FEATURE FEATURE KEY:CDS POSITION:1.. SEQUENCE DESCRIPTION SEQ ID NO:53 SEQUENCE LENGTH:4 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:54 SEQUENCE LENGTH:6 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:55 SEQUENCE LENGTH:6 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:56 SEQUENCE LENGTH:7 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:57 SEQUENCE LENGTH:12 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:58 SEQUENCE LENGTH:7 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:59 SEQUENCE LENGTH:10 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:60 SEQUENCE LENGTH:10 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:61 SEQUENCE LENGTH:6 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:62 SEQUENCE LENGTH:6 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:63 SEQUENCE LENGTH:4 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION SEQ ID NO:64 SEQUENCE LENGTH:9 SEQUENCE TYPE:AMINO ACID TOPOLOGY:LINEAR MOLECULE TYPE:PEPTIDE ORIGINAL SOURCE ORGANISM:FISH SEQUENCE DESCRIPTION

Claims: A DNA fragment having a gene naturally occuring in Pagrus major which codes for a polypeptide possessing transglutaminase activity, wherein the polypeptide possessing transglutaminase activity includes the following sequence of 694 amino acid residues (ID No. 2) A DNA fragment according to Claim 1 having the base sequence represented by the following formula (ID No. 4) A DNA fragment according to claim 1 wherein the polypeptide possessing transglutaminase activity has 695 amino acid residue and is represented by the following sequence (ID No. 3) A recombinant plasmid which comprises a DNA fragment according to any one of Claims 1 - 3 and a plasmid vector. A recombinant plasmid according to Claim 4 wherein the vector is an expression vector. A host cell transformed by a recombinant plasmid according to Claim 5. A method for the production of a polypeptide possessing transglutaminase activity, using a genetic engineering technique characterized by culturing a host cell according to Claim 6. A polypeptide possessing transglutaminase activity, obtainable by culturing a host cell according to Claim 6. A polypeptide encoded by a gene contained in a DNA fragment according to any one of claims 1 to 3. The microorganism having the accession number FERM BP-4114.

Inventors: MATSUI HIROSHI, MOTOKI MASAO, NAGASE KAZUO, NAKANISHI KAZUO, YASUEDA HISASHI, MATSUI, HIROSHI, MOTOKI, MASAO, NAGASE, KAZUO, NAKANISHI, KAZUO, YASUEDA, HISASHI, MATSUI, HIROSHI,C/O CENTRAL RESEARCH LAB., Motoki, Masao, c/o Central Research Lab., Nagase, Kazuo, c/o Central Research Lab., Nakanishi, Kazuo, c/o Central Research Lab., Yasueda, Hisashi, c/o Central Research Lab.
Applicants: AJINOMOTO KK, AJINOMOTO CO., INC.
Application year: 1993
Main classification: C12N15
IPC codes: C12N15, C12N9, C12N1